Combined dynamic alterations in urinary VEGF levels and tissue ADAM9 expression as markers for lethal phenotypic progression of prostate cancer

Chinese Journal of Physiology

Volumn 55, Issue 6, 2012, Pages 390-397

  Pen, Chen Chin ^a   Liu, Che Ming ^b   Lin, Cho Chin ^a,c   Lin, Chia Chen ^a   Hsieh, Teng Fu ^b,d   Josson, Sajni ^e   He, Yun Chi ^b   Chung, Leland W K ^e   Lin, Keh Liang ^c   Sung, Shian Ying ^b,f  

^a Department of Health   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

ADAM9; Prostate cancer; Urine VEGF

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE 9 PROTEIN; ANTINEOPLASTIC AGENT; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A;

ACCURACY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PHENOTYPE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RISK ASSESSMENT; TISSUE LEVEL; TRANSURETHRAL RESECTION; TUMOR BIOPSY; URINALYSIS; BIOPSY; DISEASE COURSE; METABOLISM; PROSTATE TUMOR; TUMOR RECURRENCE;

BIOPSY; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84868632521     PISSN: 03044920     EISSN: 26660059     Source Type: Journal    
DOI: 10.4077/CJP.2012.BAA075     Document Type: Article

References (26)

1. Bok, R.A., Halabi, S., Fei, D.T., Rodriquez, C.R., Hayes, D.F., Vogelzang, N.J., Kantoff, P., Shuman, M.A. and Small, E.J. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 61: 2533-2536, 2001.
2. Boure, T. and Vanholder, R. Biochemical and clinical evidence for uremic toxicity. Artif. Organs 28: 248-253, 2004.
3. Chan, L.W., Moses, M.A., Goley, E., Sproull, M., Muanza, T., Coleman, C.N., Figg, W.D., Albert, P.S., Menard, C. and Camphausen, K. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J. Clin. Oncol. 22: 499-506, 2004.
4. Chung, L.W., Hsieh, C.L., Law, A., Sung, S.Y., Gardner, T.A., Egawa, M., Matsubara, S. and Zhau, H.E. New targets for therapy in prostate cancer: modulation of stromal-epithelial interactions. Urology 62: 44-54, 2003.
5. Edirisinghe, I. and Rahman, I. Cigarette smoke-mediated oxidative stress, shear stress, and endothelial dysfunction: role of VEGFR2. Ann. N. Y. Acad. Sci. 1203: 66-72, 2010.
6. Fischer, O.M., Hart, S., Gschwind, A., Prenzel, N. and Ullrich, A. Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol. Cell Biol. 24: 5172-5183, 2004.
7. Fritzsche, F.R., Jung, M., Tolle, A., Wild, P., Hartmann, A., Wassermann, K., Rabien, A., Lein, M., Dietel, M., Pilarsky, C., Calvano, D., Grutzmann, R., Jung, K. and Kristiansen, G. ADAM9 Expression is a Significant and Independent Prognostic Marker of PSA Relapse in Prostate Cancer. Eur. Urol. 54: 1097-1108, 2008.
8. Gustavsson, H., Welen, K. and Damber, J.E. Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 62: 364-373, 2005.
9. Hill, P. and Marquardt, H. Plasma and urine changes after smoking different brands of cigarettes. Clin. Pharmacol. Ther. 27: 652-658, 1980.
10. Jackson, M.W., Roberts, J.S., Heckford, S.E., Ricciardelli, C., Stahl, J., Choong, C., Horsfall, D.J. and Tilley, W.D. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res. 62: 854-859, 2002.
11. Jones, A., Fujiyama, C., Turner, K., Fuggle, S., Cranston, D., Bicknell, R. and Harris, A.L. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int. 85: 276-280, 2000.
12. Joseph, I.B., Nelson, J.B., Denmeade, S.R. and Isaacs, J.T. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin. Cancer Res. 3: 2507-2511, 1997.
13. Josson, S., Anderson, C.S., Sung, S.Y., Johnstone, P.A., Kubo, H., Hsieh, C.L., Arnold, R., Gururajan, M., Yates, C. and Chung, L.W. Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy. Prostate 71: 232-240, 2011.
14. Kaygusuz, G., Tulunay, O., Baltaci, S. and Gogus, O. Microvessel density and regulators of angiogenesis in malignant and nonmalignant prostate tissue. Int. Urol. Nephrol. 39: 841-850, 2007.
15. Korivi, M., Hou, C.W., Chen, C.Y., LEE, J.P., R., k.S. and Kuo, C.H. Angiogenesis: Role of exercise training and aging. Adapt. Med. 2: 29-41, 2010.
16. Lin, C.K., Jin, J.S., Yu, C.P. and Tsai, W.C. Expression of LGR8 and related biomarkers in hepatocellular carcinoma: correlation with clinicopathological parameters. Chinese J. Physiol. 54: 161-168, 2011.
17. Mazzucchelli, R., Montironi, R., Santinelli, A., Lucarini, G., Pugnaloni, A. and Biagini, G. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 45: 72-79, 2000.
18. Miyake, H., Muramaki, M., Kurahashi, T., Yamanaka, K. and Hara, I. Urinary levels of vascular endothelial growth factor in patients with prostate cancer as a predictor of disease progression. Anticancer Res. 25: 3645-3649, 2005.
19. Neufeld, G., Cohen, T., Gengrinovitch, S. and Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13: 9-22, 1999.
20. Peduto, L. ADAM9 as a Potential Target Molecule in Cancer. Curr. Pharm. Des. 15: 2282-2287, 2009.
21. Shigemura, K., Sung, S.Y., Kubo, H., Arnold, R.S., Fujisawa, M., Gotoh, A., Zhau, H.E. and Chung, L.W. Reactive oxygen species mediate androgen receptor-and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Prostate 67: 722-731, 2007.
22. Sung, S.Y., Hsieh, C.L., Law, A., Zhau, H.E., Pathak, S., Multani, A.S., Lim, S., Coleman, I.M., Wu, L.C., Figg, W.D., Dahut, W.L., Nelson, P., Lee, J.K., Amin, M.B., Lyles, R., Johnstone, P.A., Marshall, F.F. and Chung, L.W. Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res. 68: 9996-10003, 2008.
23. Sung, S.Y., Hsieh, C.L., Wu, D., Chung, L.W. and Johnstone, P.A. Tumor Microenvironment Promotes Cancer Progression, Metastasis, and Therapeutic Resistance. Curr. Probl. Cancer 31: 36-100, 2007.
24. Sung, S.Y., Kubo, H., Shigemura, K., Arnold, R.S., Logani, S., Wang, R., Konaka, H., Nakagawa, M., Mousses, S., Amin, M., Anderson, C., Johnstone, P., Petros, J.A., Marshall, F.F., Zhau, H.E. and Chung, L.W. Oxidative Stress Induces ADAM9 Protein Expression in Human Prostate Cancer Cells. Cancer Res. 66: 9519-9526, 2006.
25. 2+ movement in PC3 human prostate cancer cells. Chinese J. Physiol. 53: 151-159, 2010.
26. Wade, T.P. and Kozlowski, P. Longitudinal studies of angiogenesis in hormone-dependent Shionogi tumors. Neoplasia 9: 563-568, 2007.